U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H23N5OS
Molecular Weight 429.537
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LHD-221

SMILES

CC(C)N1C=NC2=C1N=C(N=C2NCCC3=CC=C(O)C=C3)C4=CSC5=C4C=CC=C5

InChI

InChIKey=BGFHMYJZJZLMHW-UHFFFAOYSA-N
InChI=1S/C24H23N5OS/c1-15(2)29-14-26-21-23(25-12-11-16-7-9-17(30)10-8-16)27-22(28-24(21)29)19-13-31-20-6-4-3-5-18(19)20/h3-10,13-15,30H,11-12H2,1-2H3,(H,25,27,28)

HIDE SMILES / InChI

Molecular Formula C24H23N5OS
Molecular Weight 429.537
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including: http://www.stemcell.com/en/Products/All-Products/StemRegenin-1.aspx and https://www.caymanchem.com/product/10625

The compound StemRegenin 1 (SR1) is a selective, cell-permeable, small molecule that promotes the self-renewal of human hematopoietic stem cells in culture. SR1 is an antagonist of the aryl hydrocarbon receptor. SR1 is the first small molecule that promotes robust expansion/self-renewal of human CD34 peripheral blood and cord blood hematopoietic stem cells (HSCs). The culture of HSCs with SR1 led to a 50-fold increase in cells expressing CD34 and a 17-fold increase in cells that retain the ability to engraft immunodeficient mice. SR1 can be potentially used for ex vivo expansion of normal HSCs or leukemic stem/progenitor cells

Originator

Curator's Comment: # Scripps Research Institute; Novartis Pharmaceuticals

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35869
Gene ID: 196.0
Gene Symbol: AHR
Target Organism: Homo sapiens (Human)
127.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.
2010 Sep 10
Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling.
2012 Feb 3
Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells.
2012 Sep 27
Patents

Sample Use Guides

Unknown
Route of Administration: Unknown
SR1 was used at 1 µM final concentration (DMSO 0.01%) in the ex vivo cell culture for 7-21 days. SR1 may be refreshed every 2-3 days during the culture
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:15:51 GMT 2023
Edited
by admin
on Sat Dec 16 15:15:51 GMT 2023
Record UNII
RNE1V1F9O1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LHD-221
Code English
4-(2-((2-(BENZO(B)THIOPHEN-3-YL)-9-ISOPROPYL-9H-PURIN-6-YL)AMINO)ETHYL)PHENOL
Common Name English
LFU-835
Code English
STEMREGENIN1
Common Name English
Code System Code Type Description
FDA UNII
RNE1V1F9O1
Created by admin on Sat Dec 16 15:15:51 GMT 2023 , Edited by admin on Sat Dec 16 15:15:51 GMT 2023
PRIMARY
EPA CompTox
DTXSID70673068
Created by admin on Sat Dec 16 15:15:51 GMT 2023 , Edited by admin on Sat Dec 16 15:15:51 GMT 2023
PRIMARY
PUBCHEM
46199207
Created by admin on Sat Dec 16 15:15:51 GMT 2023 , Edited by admin on Sat Dec 16 15:15:51 GMT 2023
PRIMARY
CAS
1227633-49-9
Created by admin on Sat Dec 16 15:15:51 GMT 2023 , Edited by admin on Sat Dec 16 15:15:51 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
LHD221, an AHR antagonist facilitates the expansion of CD34-positive hematopoietic progenitors and impedes HSPC differentiation during cytokine-driven expansion in culture.